GlassScriptPhysician profile
Kevin M Berman
NPI 1740287341
$3,007.59
in general payments reported to CMS, 2019-2025
28 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $382 · 2021: $570 · 2022: $574 · 2023: $129 · 2024: $380 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $518.38 | 2021-2024 | Fortify Assura, Mitraclip |
| Boston Scientific Corporation | $426.48 | 2020-2025 | General - Therapies, Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $263.03 | 2019-2025 | Lifevest |
| Biotronik INC. | $246.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $243.62 | 2019-2020 | |
| Kci USA, INC. | $235.40 | 2019 | |
| Cleerly, INC. | $149.78 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kestra Medical Technology Services, INC. | $119.62 | 2022 | |
| Abiomed | $117.73 | 2025 | |
| Amgen INC. | $87.47 | 2021-2025 | Repatha |
| Philips North America LLC | $66.07 | 2021 | |
| Impulse Dynamics (USA) INC. | $62.42 | 2021 | |
| Medtronic, INC. | $60.23 | 2023-2024 | Endurant Iis |
| Inspire Medical Systems, INC. | $48.60 | 2024-2025 | Inspire |
| Cvrx, INC. | $47.82 | 2024 | Barostim Neo System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.23 | 2025 | Eliquis |
| Novo Nordisk INC | $39.09 | 2024 | Wegovy, Ozempic |
| Cardiva Medical, INC. | $34.62 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $26.82 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $26.65 | 2021-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $25.23 | 2025 | Opsumit |
| Advanced Oxygen Therapy INC. | $22.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.56 | 2024 | |
| Baxter Healthcare | $17.54 | 2025 | Floseal |
| Irhythm Technologies, INC. | $17.38 | 2022 | |
| Merck Sharp & Dohme LLC | $16.79 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $13.14 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.